1. The Role of mTOR in Cancer Etiology and Treatment Based on presentations from the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) May 30-June 3, 2008 Chicago, Illinois

7. MCL confirmed locally Relapsed/refractory to 2-7 prior therapies Required: Rituximab Anthracycline Alkylating agent RANDOMIZATIONRANDOMIZATION Temsirolimus 175 mg q3w then 75 mg qw Temsirolimus 175 mg q3w then 25 mg qw Investigator’s choice single agent * Temsirolimus treatment to continue until progression, death or unacceptable toxicity Adapted from Hess et al. ASCO 2008, abstract 8513. Study Design * Protocol specified (n): Gemcitabine i.v. (22), fludarabine i.v., oral (14), chlorambucil oral (3), cladribine i.v. (3), etoposide i.v. (3), cyclophosphamide oral (2) * Approved additions (n): Thalidomide oral (2), vinblastine i.v. (2) alemtuzumab i.v. (1), lenalidomide oral (1)

8. PeriodTemsirolimus 175/75 n=54 Temsirolimus 175/25 n=54 Week 1-3 Mean dose intensity, mg/wk Mean relative dose intensity 130 0.74 122 0.70 Week 4 – end of treatment Mean dose intensity, mg/wk Mean relative dose intensity 52 0.69 21 0.86 Overall exposure Mean total exposure, mg Mean dose intensity, mg/wk Mean relative dose intensity 1253 84 0.74 757 59 0.80 Dose Administration and Exposure Adapted from Hess et al. ASCO 2008, abstract 8513.

9. Temsirolimus 175/75 n=54 Temsirolimus 175/25 n=45 Investigator’s choice n=50 Median PFS, months4.83.52.0 95% CI P value vs. IC Hazard ratio 95% CI 4.2-7.4 0.0026 0.47 0.28-0.77 2.0-6.2 0.0464 0.61 0.37-1.00 1.6-2.5 Date of data cutoff: 19 July 2007 (independent assessment) Progression-free Survival (ITT) Excluding Patients with Blastoid Histology Adapted from Hess et al. ASCO 2008, abstract 8513.